Brief: Fulcrum Therapeutics Q2 Basic EPS USD 0.89
31/07/2024 12:00
Jul 31 (Reuters) - Fulcrum Therapeutics Q2 operating expenses USD 27.508 million. * Q2 operating income USD 52.492 million vs. IBES estimate USD 361.4 thousand * Q2 collaboration revenue USD 80 million * Q2 net income USD 55.409 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Fulcrum to merge with Slate in all-stock deal after drug setback